US EditionDynavax Issues Statement and Mails Letter to Stockholders Emphasizing Record Financial Results and Continued Momentum
- Dynavax Technologies Corporation issued a statement on May 7, 2025, from Emeryville, California, emphasizing record Q1 2025 financial results and continued momentum ahead of its June 11 Annual Meeting.
- The statement responds to Deep Track Capital's recent investor presentation, which Dynavax characterizes as misleading and focused on a short-term capital return that threatens long-term growth and stockholder value.
- Dynavax reported total revenue of $68.2 million in Q1 2025, a 34% increase from $50.8 million in Q1 2024, with HEPLISAV-B net product revenue rising 36% to $65 million and adjusted EBITDA improving to negative $4 million.
- Since November 2024, the company has repurchased shares totaling $172 million, representing more than 85% completion of its $200 million buyback initiative, and anticipates achieving an adjusted EBITDA of no less than $75 million for the entire year 2025.
- Dynavax urges stockholders to vote for its four qualified board nominees to sustain the current strategic plan, which leverages its CpG 1018 adjuvant and advances a diversified vaccine pipeline to drive long-term growth and value.
Insights by Ground AI
Does this summary seem wrong?
19 Articles
19 Articles
All
Left
Center
8
Right
Albuquerque Journal+18 Reposted by 18 other sources
Dynavax Issues Statement and Mails Letter to Stockholders Emphasizing Record Financial Results and Continued Momentum
Deep Track's Misleading Investor Presentation Demonstrates its Single-Minded Approach to Abandon Long-Term Value Opportunities in Exchange for Short-Term Return
·Albuquerque, United States
Read Full ArticleCoverage Details
Total News Sources19
Leaning Left0Leaning Right0Center8Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage